骨肉腫の世界市場レポート 2025年

骨肉腫市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.8％で9億9,000万米ドルに成長します。予測期間中の成長は、個別化医療の採用の増加、希少がんに対する認識の高まり、政府と民間部門の研究資金の増加、遺伝子変異の発生率の上昇、免疫療法による治療成績改善の可能性などに起因すると考えられます。この期間に予想される主要動向には、標的療法の開発、免疫療法の発展、個別化医療の採用、遺伝子編集技術の進歩、化学療法薬の革新、画像診断技術の向上、手術技術の進歩などがあります。

がんの有病率の増加は、今後数年間の骨肉腫市場の拡大を促進すると予想されます。がんは、健康な組織に侵入して損傷を与える異常細胞の制御不能な増殖と拡散によって特徴づけられる疾患です。高齢化、ライフスタイルの変化、環境暴露、感染症、遺伝的素因など、いくつかの要因ががんの発生率上昇に寄与しています。骨肉腫治療は、治療戦略の進歩、早期発見技術の向上、骨がんの理解の深化において重要な役割を果たしています。これらの開発は、患者ケアの向上、生存率の改善、より効果的な治療法の創出につながります。例えば、2024年5月、米国の政府機関である国立がんラボは、2022年に世界で約2,000万人の新規がん患者と970万人のがん関連死亡者が記録されたと報告しました。予測によれば、この数字は2040年までに年間2,990万人の新規がん患者と1,530万人の死亡者に増加する可能性があります。その結果、がんの有病率の上昇が骨肉腫市場の成長に拍車をかけています。

骨肉腫市場の主要企業は、治療効果を高め、副作用を最小限に抑え、患者の生存転帰を改善するため、希少疾病用医薬品（オーファンドラッグ）に指定された先進医薬品の開発を優先しています。希少疾病用医薬品の指定は、希少疾病を治療するために設計された医薬品または生物製剤に規制当局から与えられる特別なステータスであり、税制優遇措置、臨床検査支援、市場独占権の延長などのメリットを記載しています。例えば、米国の製薬会社リサータ・セラピューティクス社は2024年4月、同社の治験薬LSTA1が米国食品医薬品局（FDA）から希少疾病用医薬品の指定を受けたと発表しました。LSTA1は、新規の取り込み経路を活性化し、骨肉腫腫瘍への薬剤の浸透と蓄積を高めると同時に、腫瘍微小環境を改変して免疫療法への反応性を改善する可能性があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の骨肉腫PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の骨肉腫市場：成長率分析
• 世界の骨肉腫市場の実績：規模と成長、2019～2024年
• 世界の骨肉腫市場の予測：規模と成長、2024～2029年、2034年
• 世界の骨肉腫総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の骨肉腫市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 髄内骨肉腫
• 皮質近傍骨肉腫
• 骨格外骨肉腫
• 世界の骨肉腫市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 手術
• 化学療法
• 放射線治療
• 標的療法
• 免疫療法
• 世界の骨肉腫市場：年齢層別、実績と予測、2019～2024年、2024～2029年、2034年
• 小児
• 成人
• 世界の骨肉腫市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• オンラインチャネル
• オフラインチャネル
• 世界の骨肉腫市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院とクリニック
• 診断センター
• 学術研究機関
• 世界の骨肉腫市場、髄内骨肉腫のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 骨幹端部骨肉腫
• 骨幹骨肉腫
• 世界の骨肉腫市場、皮質近傍骨肉腫のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• パロスティアル骨肉腫
• 骨膜骨肉腫
• 世界の骨肉腫市場、骨外性骨肉腫のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 一次骨格外骨肉腫
• 二次骨格外骨肉腫

第7章 地域別・国別分析

• 世界の骨肉腫市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の骨肉腫市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 骨肉腫市場：競合情勢
• 骨肉腫市場：企業プロファイル
  • Pfizer Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Bayer AG

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Bristol-Myers Squibb Company
• Novartis AG
• AstraZeneca PLC
• GSK plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Baxter International Inc.
• Hikma Pharmaceuticals PLC
• Spectrum Pharmaceuticals Inc.
• Mylan N.V.
• Bellicum Phamaceuticals Inc.
• ADVAXIS Inc.
• Iovance BIoTherapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 骨肉腫市場、2029年：新たな機会を提供する国
• 骨肉腫市場、2029年：新たな機会を提供するセグメント
• 骨肉腫市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Osteosarcoma is a malignant tumor that develops in bone-forming cells, primarily affecting the long bones of the body. It most commonly impacts teenagers and young adults, causing symptoms such as pain, swelling, and difficulty in movement.

The primary types of osteosarcoma include intramedullary osteosarcoma, juxtacortical osteosarcoma, and extraskeletal osteosarcoma. Intramedullary osteosarcoma, the most common form, affects long bones such as the arms and legs. Originating in the bone marrow, it grows and spreads rapidly, often leading to fractures or swelling, particularly in teenagers and young adults. Treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. It is used for both pediatric and adult patients and is distributed through online and offline channels. The disease is managed in various settings, including hospitals and clinics, diagnostic centers, and academic and research institutions.

The osteosarcoma market research report is one of a series of new reports from The Business Research Company that provides osteosarcoma market statistics, including the osteosarcoma industry's global market size, regional shares, competitors with an osteosarcoma market share, detailed osteosarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the osteosarcoma industry. This osteosarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The osteosarcoma market size has grown strongly in recent years. It will grow from $0.71 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to increasing cancer awareness, improved treatment options, a rise in bone cancer incidence, advancements in healthcare infrastructure, growth in research and clinical trials, and the development of targeted therapies and immunotherapies.

The osteosarcoma market size is expected to see strong growth in the next few years. It will grow to $0.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to the rising adoption of personalized medicine, increasing awareness of rare cancers, growing government and private sector funding for research, a rising incidence of genetic mutations, and the potential for improved treatment outcomes with immunotherapy. Key trends expected during this period include the development of targeted therapies, advancements in immunotherapies, the adoption of personalized medicine, progress in gene editing techniques, innovation in chemotherapy drugs, improvements in diagnostic imaging technologies, and advancements in surgical techniques.

The increasing prevalence of cancer is expected to drive the expansion of the osteosarcoma market in the coming years. Cancer is a disease marked by the uncontrolled growth and spread of abnormal cells, which can invade and damage healthy tissues. Several factors contribute to the rising incidence of cancer, including an aging population, lifestyle changes, environmental exposures, infections, and genetic predisposition. Osteosarcoma treatment plays a crucial role in advancing therapeutic strategies, improving early detection techniques, and deepening the understanding of bone cancer. These developments lead to better patient care, improved survival rates, and the creation of more effective therapies. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that in 2022, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded worldwide. Projections indicate that these numbers could increase to 29.9 million new cases and 15.3 million deaths annually by 2040. Consequently, the rising prevalence of cancer is fueling the growth of the osteosarcoma market.

Major companies in the osteosarcoma market are prioritizing the development of advanced drugs with orphan drug designation to enhance treatment effectiveness, minimize side effects, and improve survival outcomes for patients. Orphan drug designation is a special status granted by regulatory agencies to drugs or biologics designed to treat rare diseases, offering benefits such as tax incentives, clinical trial support, and extended market exclusivity. For instance, in April 2024, Lisata Therapeutics Inc., a US-based pharmaceutical company, announced that its investigational drug LSTA1 received orphan drug designation from the US Food and Drug Administration (FDA). LSTA1 is designed to activate a novel uptake pathway, enhancing drug penetration and accumulation in osteosarcoma tumors while potentially modifying the tumor microenvironment to improve responsiveness to immunotherapies.

In May 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired QSAM Biosciences Inc. for an undisclosed amount. This acquisition is intended to expand Telix Pharmaceuticals' oncology portfolio, reinforce its expertise in targeted cancer therapies, and strengthen its capabilities in rare disease treatments, particularly osteosarcoma. QSAM Biosciences Inc. is a US-based company specializing in osteosarcoma drug development.

Major players in the osteosarcoma market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Hikma Pharmaceuticals PLC, Spectrum Pharmaceuticals Inc., Mylan N.V., Bellicum Phamaceuticals Inc., ADVAXIS Inc., Iovance Biotherapeutics Inc.

North America was the largest region in the osteosarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in osteosarcoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the osteosarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osteosarcoma market consists of revenues earned by entities by providing services such as diagnostic services, and supportive care solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteosarcoma market also includes sales of methotrexate, doxorubicin, prosthetic implants, and immune checkpoint inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osteosarcoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osteosarcoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for osteosarcoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osteosarcoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Intramedullary Osteosarcoma; Juxtacortical Osteosarcoma; Extraskeletal Osteosarcoma
• 2) By Treatment Type: Surgery; Chemotherapy; Radiation Therapy; Targeted Therapy; Immunotherapy
• 3) By Age Group: Pediatric; Adult
• 4) By Distribution Channel: Online Channel; Offline Channel
• 5) By End User: Hospitals And Clinics; Diagnostic Centers; Academic And Research Organizations
• Subsegments:
• 1) By Intramedullary Osteosarcoma: Metaphyseal Osteosarcoma; Diaphyseal Osteosarcoma
• 2) By Juxtacortical Osteosarcoma: Parosteal Osteosarcoma; Periosteal Osteosarcoma
• 3) By Extraskeletal Osteosarcoma: Primary Extraskeletal Osteosarcoma; Secondary Extraskeletal Osteosarcoma
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Osteosarcoma Market Characteristics

3. Osteosarcoma Market Trends And Strategies

4. Osteosarcoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Osteosarcoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Osteosarcoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Osteosarcoma Market Growth Rate Analysis
• 5.4. Global Osteosarcoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Osteosarcoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Osteosarcoma Total Addressable Market (TAM)

6. Osteosarcoma Market Segmentation

• 6.1. Global Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intramedullary Osteosarcoma
• Juxtacortical Osteosarcoma
• Extraskeletal Osteosarcoma
• 6.2. Global Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Chemotherapy
• Radiation Therapy
• Targeted Therapy
• Immunotherapy
• 6.3. Global Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult
• 6.4. Global Osteosarcoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Channel
• Offline Channel
• 6.5. Global Osteosarcoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Diagnostic Centers
• Academic And Research Organizations
• 6.6. Global Osteosarcoma Market, Sub-Segmentation Of Intramedullary Osteosarcoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metaphyseal Osteosarcoma
• Diaphyseal Osteosarcoma
• 6.7. Global Osteosarcoma Market, Sub-Segmentation Of Juxtacortical Osteosarcoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parosteal Osteosarcoma
• Periosteal Osteosarcoma
• 6.8. Global Osteosarcoma Market, Sub-Segmentation Of Extraskeletal Osteosarcoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Extraskeletal Osteosarcoma
• Secondary Extraskeletal Osteosarcoma

7. Osteosarcoma Market Regional And Country Analysis

• 7.1. Global Osteosarcoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Osteosarcoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Osteosarcoma Market

• 8.1. Asia-Pacific Osteosarcoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Osteosarcoma Market

• 9.1. China Osteosarcoma Market Overview
• 9.2. China Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Osteosarcoma Market

• 10.1. India Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Osteosarcoma Market

• 11.1. Japan Osteosarcoma Market Overview
• 11.2. Japan Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Osteosarcoma Market

• 12.1. Australia Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Osteosarcoma Market

• 13.1. Indonesia Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Osteosarcoma Market

• 14.1. South Korea Osteosarcoma Market Overview
• 14.2. South Korea Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Osteosarcoma Market

• 15.1. Western Europe Osteosarcoma Market Overview
• 15.2. Western Europe Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Osteosarcoma Market

• 16.1. UK Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Osteosarcoma Market

• 17.1. Germany Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Osteosarcoma Market

• 18.1. France Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Osteosarcoma Market

• 19.1. Italy Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Osteosarcoma Market

• 20.1. Spain Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Osteosarcoma Market

• 21.1. Eastern Europe Osteosarcoma Market Overview
• 21.2. Eastern Europe Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Osteosarcoma Market

• 22.1. Russia Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Osteosarcoma Market

• 23.1. North America Osteosarcoma Market Overview
• 23.2. North America Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Osteosarcoma Market

• 24.1. USA Osteosarcoma Market Overview
• 24.2. USA Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Osteosarcoma Market

• 25.1. Canada Osteosarcoma Market Overview
• 25.2. Canada Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Osteosarcoma Market

• 26.1. South America Osteosarcoma Market Overview
• 26.2. South America Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Osteosarcoma Market

• 27.1. Brazil Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Osteosarcoma Market

• 28.1. Middle East Osteosarcoma Market Overview
• 28.2. Middle East Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Osteosarcoma Market

• 29.1. Africa Osteosarcoma Market Overview
• 29.2. Africa Osteosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Osteosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Osteosarcoma Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Osteosarcoma Market Competitive Landscape And Company Profiles

• 30.1. Osteosarcoma Market Competitive Landscape
• 30.2. Osteosarcoma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Osteosarcoma Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. Novartis AG
• 31.4. AstraZeneca PLC
• 31.5. GSK plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Baxter International Inc.
• 31.10. Hikma Pharmaceuticals PLC
• 31.11. Spectrum Pharmaceuticals Inc.
• 31.12. Mylan N.V.
• 31.13. Bellicum Phamaceuticals Inc.
• 31.14. ADVAXIS Inc.
• 31.15. Iovance Biotherapeutics Inc.

32. Global Osteosarcoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Osteosarcoma Market

34. Recent Developments In The Osteosarcoma Market

35. Osteosarcoma Market High Potential Countries, Segments and Strategies

• 35.1 Osteosarcoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Osteosarcoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Osteosarcoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer